特發性肺纖維化治療市場規模、佔有率和成長分析（按藥物類別、給藥途徑、作用機制、分銷管道、最終用途和地區）- 產業預測 2025-2032

特發性肺纖維化治療市場規模在 2023 年價值 46 億美元，預計將從 2024 年的 49.2 億美元成長到 2032 年的 83.9 億美元，預測期內（2025-2032 年）的複合年成長率為 6.9%。

全球特發性肺纖維化 (IPF) 治療市場正在經歷顯著成長，這主要是由於人口的增加和對呼吸系統疾病認知的提高。 IPF 的特徵是肺部疤痕形成，影響呼吸，是肺纖維化的主要形式。目前的治療方法包括FDA核准的藥物療法，例如尼達尼布和Pirfenidone，而肺移植仍是晚期疾病患者的有效解決方案。近年來，研發活動不斷增多，帶來了有前景的治療方法創新和候選藥物。此外，製藥公司和研究機構之間的策略合作正在推動有效的 IPF治療方法的開發，進一步推動市場活力並改善患者的治療效果。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

特發性肺纖維化治療市場規模（依藥物類別和複合年成長率） (2025-2032)

• 市場概況
• Pirfenidone
• 尼達尼布
• 其他

特發性肺纖維化治療市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概況
• 口服
• 注射

特發性肺纖維化治療市場規模（按作用機制和複合年成長率） (2025-2032)

• 市場概況
• 抗纖維化藥物
• 蛋白酪氨酸激酶抑制劑
• 其他

特發性肺纖維化治療市場規模（按分銷管道和複合年成長率）（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

特發性肺纖維化治療市場規模（按最終用途和複合年成長率分類）（2025-2032 年）

• 市場概況
• 醫院
• 診所
• 居家照護

特發性肺纖維化治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Boehringer Ingelheim International GmbH（Germany）
• Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（UK）
• Biogen（USA）
• FibroGen, Inc.（USA）
• Bristol Myers Squibb Company（USA）
• GNI Group Ltd.（Japan）
• Cipla Inc.（India）
• Amgen Inc.（USA）
• Mission Therapeutics（UK）
• Galapagos NV（Belgium）
• Promedior, Inc.（USA）
• Zai Lab Limited（China）
• Pliant Therapeutics, Inc.（USA）
• Kadmon Holdings, Inc.（USA）
• Genentech, Inc.（USA）
• Sanofi（France）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• United Therapeutics Corporation（USA）

結論和建議

Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 4.92 billion in 2024 to USD 8.39 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global idiopathic pulmonary fibrosis (IPF) treatment market has seen substantial growth, primarily driven by an increasing population and heightened awareness of respiratory diseases. IPF, characterized by lung scarring that impairs breathing, is the predominant form of pulmonary fibrosis. Current treatment options include FDA-approved pharmacological therapies like Nintedanib and Pirfenidone, while lung transplantation remains a viable solution for patients in advanced stages of the disease. Recent years have witnessed a surge in R&D activities, resulting in promising therapeutic innovations and new drug candidates. Moreover, strategic collaborations between pharmaceutical companies and research institutions are propelling the development of effective IPF treatments, further invigorating market dynamics and enhancing patient care outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Idiopathic Pulmonary Fibrosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Idiopathic Pulmonary Fibrosis Treatment Market Segments Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented by Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use and region. Based on Drug Class, the market is segmented into Pirfenidone, Nintedanib and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End-use, the market is segmented into Hospitals, Clinics and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Idiopathic Pulmonary Fibrosis Treatment Market

A significant factor propelling the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the growing incidence of IPF, especially among the elderly demographic. As the disease becomes more common worldwide, there is an escalating demand for effective treatment modalities. This increase in diagnosed cases highlights the urgent need for pharmaceutical solutions and therapies that can not only decelerate the progression of the disease but also enhance the overall quality of life for patients. Consequently, the continual rise in the prevalence of IPF serves as a vital driver for the expansion and innovation within this treatment market.

Restraints in the Idiopathic Pulmonary Fibrosis Treatment Market

A significant challenge facing the idiopathic pulmonary fibrosis (IPF) treatment market is the prohibitive cost associated with therapies. The expenses tied to medications and diagnostic procedures can be substantial, potentially restricting access to essential treatments, particularly in areas where healthcare resources are scarce or insurance coverage is insufficient. This financial barrier can hinder the availability and affordability of effective therapeutic options, ultimately affecting patient outcomes and limiting the overall growth potential of the IPF treatment market in various regions, particularly those with less developed healthcare infrastructure. Addressing these cost-related issues is crucial for improving patient access to necessary care.

Market Trends of the Idiopathic Pulmonary Fibrosis Treatment Market

The idiopathic pulmonary fibrosis (IPF) treatment market is witnessing a significant shift towards personalized medicine and precision therapeutics, reflecting a broader trend in healthcare. As research progresses, the emphasis has moved from understanding the disease's pathogenesis to developing tailored treatment strategies aimed at individual patient profiles. Notable advancements in pharmacotherapy, particularly with the introduction of Nintedanib and Pirfenidone, have demonstrated efficacy in slowing the decline in forced vital capacity (FVC) and improving patient quality of life. This growing focus on individualized treatment plans is poised to drive market growth, as stakeholders aim to enhance therapeutic outcomes and optimize patient care in IPF management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Pirfenidone
• Nintedanib
• Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Mode of Action & CAGR (2025-2032)

• Market Overview
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings

Global Idiopathic Pulmonary Fibrosis Treatment Market Size & CAGR (2025-2032)

• North America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GNI Group Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mission Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promedior, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zai Lab Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pliant Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kadmon Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations